Evelio R. Gonzalez Dalmau

Prof. Dr. Evelio R. Gonzalez Dalmau

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2013 in Nanoscale
Verified
Journal Article
Closed access
PDF file
ARAmalia Ruiz
Amalia Ruiz
YHY. Hernández
Y. Hernández
CCC. Cabal
C. Cabal
EDEvelio R. Gonzalez Dalmau
Evelio R. Gonzalez Dalmau
SVSabino Veintemillas-Verdaguer
Sabino Veintemillas-Verdaguer
MMMaría del Puerto Morales
María del Puerto Morales
The influence of polyethylene glycol (PEG) grafting on the pharmacokinetics, biodistribution and elimination of iron oxide nanoparticles is studied in this work. Magnetite nanoparticles (12 nm) were obtained via thermal decomposition of an iron coordination complex as a precursor. Particles were coated with meso-2,3-dimercaptosuccinic acid (DMSA) and conjugated to PEG-derived molecules by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) chemistry. Using a rat model, we explored the nanoparticle biodistribution pattern in blood and in different organs (liver, spleen and lungs) after intravenous administration of the product. The time of residence in blood was measured from the evolution of water proton relaxivities with time and Fe analysis in blood samples. The results showed that the residence time was doubled for PEG coated nanoparticles and consequently particle accumulation in liver and spleen was reduced. Post-mortem histological analyses showed no alterations in the liver and confirm heterogeneous distribution of NPs in the organ, in agreement with magnetic measurements and iron analysis. Finally, by successive magnetic resonance images we studied the evolution of contrast in the liver and measured the absorption, time of residence and excretion of nanoparticles in the liver during a one month period. On the basis of these results we propose different metabolic routes that determine the fate of magnetic nanoparticles.

28 January 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
DPDominique Piché
Dominique Piché
ITIsabella Tavernaro
Isabella Tavernaro
JFJana Fleddermann
Jana Fleddermann
JLJuan Gabriel Lozano
Juan Gabriel Lozano
AVAakash Varambhia
Aakash Varambhia
NGNicole Grobert
Nicole Grobert
Extraordinarily small (2.4 nm) cobalt-ferrite nanoparticles (ESCIoNs) were synthesised by a one-pot thermal decomposition approach to study their potential as MRI contrast agents. Fine size control was achieved using oleylamine alone, and annular dark-field scanning transmission electron microscopy revealed highly-crystalline cubic spinel particles with atomic-resolution. Ligand exchange with dimercaptosuccinic acid rendered the particles stable in physiological conditions with a hydrodynamic diameter of ∽12 nm. The particles displayed superparamagnetic properties, and a low r2/r1 ratio suitable for a T1 contrast agent. The particles were functionalised with bile-acid which improved biocompatibility by significant reduction of reactive oxygen species generation and is a first step towards liver-targeted T1 MRI. Our study demonstrates the potential of ESCIoNs as T1 MRI contrast agents.

13 December 2023 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
SSSaily Sosa
Saily Sosa
GBGiosmany Bringas
Giosmany Bringas
NUNelky Urrutia
Nelky Urrutia
APAna Ivis Peñalver
Ana Ivis Peñalver
DLDanay López
Danay López
LPLeslie Pérez
Leslie Pérez
Background: NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, apoptosis and cognitive deficit in an Alzheimer’s disease (AD) models. The aim of this study was to assess efficacy and safety of neuroEPO plus. Methods: This was a double-blind, randomized, placebo-controlled, phase 2–3 trial involving participants ≥ 50 years of age with mild-to-moderate AD clinical syndrome. Participants were randomized in a 1:1:1 ratio to receive 0.5 or 1.0 mg of neuroEPO plus or placebo intranasally 3 times/week for 48 weeks. The primary outcome was change in the 11-item cognitive subscale of the AD Assessment Scale (ADAS-Cog11) score from baseline to 48 weeks (range, 0 to 70; higher scores indicate greater impairment). Secondary outcomes included CIBIC+, GDS, MoCA, NPI, Activities of Daily Living Scales, cerebral perfusion, and hippocampal volume. Results: A total of 174 participants were enrolled and 170 were treated (57 in neuroEPO plus 0.5 mg, 56 in neuroEPO plus 1.0 mg and 57 in placebo group). Mean age, 74.0 years; 121 (71.2%) women and 85% completed the trial. The median change in ADAS-Cog11 score at 48 weeks was −3.0 (95% CI, −4.3 to −1.7) in the 0.5 mg neuroEPO plus group, −4.0 (95% CI, −5.9 to −2.1) in the 1.0 mg neuroEPO plus group and 4.0 (95% CI, 1.9 to 6.1) in the placebo group. The difference of neuroEPO plus 0.5 mg vs. placebo was 7.0 points (95% CI, 4.5–9.5) P = 0.000 and between the neuroEPO plus 1.0 mg vs. placebo was 8.0 points (95% CI, 5.2–10.8) P = 0.000. NeuroEPO plus treatment induced a statistically significant improvement in some of clinical secondary outcomes vs. placebo including CIBIC+, GDS, MoCA, NPI, and the brain perfusion. Conclusions: Among participants with mild-moderate Alzheimer’s disease clinical syndrome, neuroEPO plus improved the cognitive evaluation at 48 weeks, with a very good safety profile. Larger trials are warranted to determine the efficacy and safety of neuroEPO plus in Alzheimer’s disease. Trial registration: https://rpcec.sld.cu Identifier: RPCEC00000232.

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
PDF file
LPLeslie Pérez
Leslie Pérez
SSSaily Sosa
Saily Sosa
GBGiosmany Bringas
Giosmany Bringas
DLDanay López
Danay López
CVCarmen Valenzuela
Carmen Valenzuela
NUNelky Urrutia
Nelky Urrutia

1 July 2021 in Neurology Perspectives
Verified
Journal Article
Open access
AVA. Viña-González
A. Viña-González
IGI. Rodriguez Gil
I. Rodriguez Gil
SPS. Sosa Pérez
S. Sosa Pérez
NAN. Urrutia Amable
N. Urrutia Amable
LRL. Pérez Ruiz
L. Pérez Ruiz
EDEvelio R. Gonzalez Dalmau
Evelio R. Gonzalez Dalmau

26 March 2018 in Applied Magnetic Resonance
Verified
Journal Article
Open access
PDF file
CMCarlos Cabal Mirabal
Carlos Cabal Mirabal
AGAdolfo Fernández García
Adolfo Fernández García
MGManuel Lores Guevara
Manuel Lores Guevara
EDEvelio R. Gonzalez Dalmau
Evelio R. Gonzalez Dalmau
LDLeonardo Oramas Díaz
Leonardo Oramas Díaz
The potentials of the magnetic resonance (MR) methods in the research of biomedical systems have been demonstrated during the 70 years of its existence. It is presented that the Cuban experience in quantitative magnetic resonance associated with molecular, preclinical and clinical studies of significant diseases and drugs development. MR “in vitro” and “in vivo” studies of sickle cell disease, the diabetic foot ulcer, the brain tumor response and the magnetic nano-particle pharmacokinetics, are presented as example. Furthermore, contributions and restrictions of magnetic resonance to diagnostic and optimization of therapeutic pathways are discussed in some concrete cases.